Bruker and ImaBiotech Announces Collaboration
News Jun 21, 2013
Bruker and ImaBiotech have announced a collaboration for the distribution of ImaBiotech’s Quantinetix™ software. The Quantinetix software is the first independent multi-format software for MALDI instruments that quantifies and normalizes molecules.
Mass spectrometry MALDI imaging is a technique that allows for the direct detection of drugs and metabolites in tissue, and it is increasingly being adopted as a tool for pharmaceutical drug discovery and development.
But the absolute quantification of MALDI imaging data is challenging due to the complex matrix used (intact tissue) and the associated suppression of the ions that are essential to the measurement process.
ImaBiotech, a leading service provider for MALDI imaging, has incorporated its special quantification methods into the Quantinetix™ dedicated software package to address these challenges.
Quantinetix™ is user-friendly software that provides quantitation of target compounds following mass spectrometry imaging experiments.
It normalizes and quantifies molecules in several ways, providing images and quantitation of target compounds in over 25 organs when used for whole body distribution imaging, as well as for individual organs in targeted applications.
Dr. Sören-Oliver Deininger, Market Area Manager for MALDI Imaging at Bruker, noted, “ImaBiotech‘s Quantinetix™ software has helped transform MALDI imaging into a quantitative technique. With this collaboration, we are now able to directly provide our customers with the benefits of Quantinetix™, enabling them to achieve true quantitative results with their Bruker MALDI molecular imaging solution.”
Dr. Jonathan Stauber, CEO of ImaBiotech, added, “We are pleased to partner with Bruker. ImaBiotech’s know-how and efficiency in imaging complement Bruker’s renowned expertise in mass spectrometry. With this agreement, we are now able to offer this unparalleled technology to molecular researchers in the worldwide pharmaceutical and biomedical research industries.”
An artificial intelligence (AI) approach based on deep learning convolutional neural network (CNN) could identify nuanced mammographic imaging features specific for recalled but benign (false-positive) mammograms and distinguish such mammograms from those identified as malignant or negative.
8th Edition of International Conference and Exhibition on Separation Techniques
Jul 29 - Jul 30, 2019
International Women Health and Breast Cancer Conference
Jul 03 - Jul 05, 2019
2nd International Conference on Biological & Pharmaceutical Sciences
Jul 12 - Jul 13, 2019